Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-20,600
Closed -$4K 3400
2022
Q1
$4K Buy
+20,600
New +$3.47M ﹤0.01% 3343
2021
Q4
Sell
-20,600
Closed -$8K 3379
2021
Q3
$8K Buy
+20,600
New +$7.6M ﹤0.01% 3336

Other funds holding MRNA

Nuveen's MRNA Position: Q1 2026 in Review

Nuveen reduced its Moderna (MRNA) stake by 4.1% in Q1 2026, selling an estimated $2.17M and leaving 1,078,194 shares worth $54.8M. The position accounts for 0.01% of the portfolio, ranked #604.

Nuveen first reported a position in MRNA in Q2 2019 and has held it in 28 quarters since. The position peaked at $490M in Q3 2021. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Nuveen held 1,078,194 shares of Moderna worth $54.8M as of Q1 2026.
  • Nuveen sold 46,508 Moderna shares in Q1 2026, an estimated $2.17M.
  • Moderna made up 0.01% of Nuveen's portfolio in Q1 2026, its #604 holding.
  • Nuveen first reported a position in Moderna in Q2 2019 and has held it in 28 quarters since.
  • Nuveen's Moderna position peaked at $490M in Q3 2021.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.